Global Yersiniosis Diagnostics and Treatment Market

Yersiniosis Diagnostics & Treatment Market Analysis

The Global Yersiniosis Diagnostics and Treatment Market is expected to register a CAGR of 6.8% during the forecast period.

The COVID-19 outbreak is a rare public health concern that has had a huge global impact on the market globally as hospital and healthcare services were severely curtailed due to social exclusion and the supply chain was hampered. The exceptional rise in coronavirus-infected patients, and limited access to alternate primary care services, sped up the decline in non-COVID-19-related diagnoses, such as Yersiniosis. The reported cases of Yersiniosis were fewer in 2020 than in 2019 due to the decrease in footfall in hospitals and clinics. For instance, according to the 2020 Surveillance Atlas of Infectious Diseases by the European Centre for Disease Prevention and Control, the reported cases of Yersiniosis in the European Union decreased in 2020 as compared to the previous year. However, with the decreasing COVID-19 cases and large-scale vaccination, the diagnosis of Yersiniosis is expected to increase and the studied market is anticipated to regain its potential over the forecast period.

Therefore, the Yersiniosis diagnostics and treatment market will impede around the world with the emergence of the COVID-19 pandemic, but it will have a positive impact on the decreasing cases of COVID-19. After the COVID-19's impact has diminished, the market in some regions will gradually demonstrate consistent growth.

The market is expected to grow due to the high prevalence of Yersiniosis in Northern Europe and countries in Central Europe and improved diagnostic techniques. According to the 2020 Surveillance Atlas of Infectious Diseases by the European Centre for Disease Prevention and Control, the overall notification rate of 1.7 per 100 000 population remained stable from 2015 to 2020 in the European Union. But the highest notification rates were found in countries of Northern and Central Europe. According to the same source, in 2020 the highest Incidence rate of 7.09 per 100 000 population was found in Denmark. Thus, the above increase in the prevalence of Yersiniosis in some regions may have a positive impact on the Yersniosis diagnosis market and treatment during the forecast period.

One of the major reasons for Yersiniosis's spread is the consumption of contaminated food. The symptoms of infected young children include fever, abdominal pain, and diarrhea. In May 2022, World Health Organization published that, children under 5 years of age carry 40% of the foodborne disease burden, with 125 000 deaths every year. This increase in foodborne diseases may indirectly have a positive impact on enteric bacterial infections like Yersiniosis. Thus, the increase in foodborne diseases may help the growth of the Yersiniosis diagnostics and treatment market in the studied period.

The advent of more advanced diagnostic technologies like realtime PCR, ELISA, and Luminex Immunoassay helps in the identification of enteropathogenic Yersinia species by differentiation of Yersinia enterocolitica and Yersinia pseudotuberculosis. These improved diagnosis methods help in Yersiniosis diagnostics and treatment market help to witness high growth over the forecast period. However, a lack of awareness in developing and underdeveloped countries on Yersiniosis disease, diagnosis, and treatment will impede the market.

Yersiniosis Diagnostics & Treatment Market Trends

ELISA is Expected to Have a Major Share Over the Forecast Period

The disease diagnosis segment is expected to hold a major share due to the increasing application of enzyme-linked immunosorbent assay (ELISA) tests in the diagnosis of Yersiniosis. It is a commonly used in vitro test to detect antibodies in the blood. ELISA test can be applied in many diagnostic tests like detection and measurement of antibodies in the sample against infectious disease, tumor markers, hormone levels, and drug abuse. ELISA for Yersinia is a quantitative in vitro test for the detection and safe identification of antibodies against plasmid-coded virulence proteins. Thus, quantitative ELISA helps in diagnosing the disease severity which is a significant factor for the growth of the Yersiniosis diagnostics market in the forecast period.

In February 2022, the National Library of Medicine published an article that depicts the advantages and factors that can interfere with ELISA in diagnosing infections. Similarly, the National Library of Medicine published in April 2022, that serologic techniques to identify IgG, IgA, and IgM, such as ELISA and immunoblotting, are extensively utilized in Europe and Japan but less so in the United States. The data helps for differentiation of Yersinia enterocolitica and Yersinia pseudotuberculosis using disease-specific antigens in the ELISA test. These advancements in the ELISA will improve the growth of the market in the forecasted period.

North America is Expected to Dominate the Market Over the Forecast Period

North America is anticipated to have a significant share in the market, owing to the well-established healthcare infrastructure, sophisticated diagnostics, and significant notification rates in North American regions.

In 2020, Public Health Ontario published that, there are about 197 cases of Yersiniosis and 9 hospitalizations with a notification rate of 1.3 per 100 000 population. According to the Centers for Disease Control and Prevention reviewed in 2019, Yersiniosis is most frequently reported in northern Europe (especially Scandinavia), Japan, and Canada. It is not a condition that is required to be reported in the United States. About 92% of infections in the United States with known species information are caused by Yersinia enterocolitica, which is also responsible for an estimated 117,000 illnesses, 640 hospitalizations, and 35 fatalities annually. The significant cases reported in North America may also have a significant growth in the forecast market.

Yersiniosis Diagnostics & Treatment Industry Overview

The Yersiniosis diagnostics and treatment are fragmented in nature due to the presence of several companies operating globally. The major players include Surmodics IVD, Inc, Mikrogen GmbH, CerTest Biotec, Laboratory Corporation of America Holdings, Hologic, Inc, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Thermo Fisher Scientific, Virchow Laboratories Limited, Zhejiang Jinhua CONBA Bio-pharm.

Yersiniosis Diagnostics & Treatment Market Leaders

Yersiniosis Diagnostics & Treatment Market News

• In May 2021, CerTest announced that it has reached the final stage in the extension of its production capacity and the enlargement of the plant located in San Mateo de Gallego, in Zaragoza. In 2021, the company also started working on new production lines for various diagnostic tests.
• In November 2019, CerTest obtained the Aragon Social Responsibility mark from the government of Aragon which implies the confirmation of CerTest Biotec's commitment to the social principles of awareness, commitment, transparency, and that make up the Aragon Social Responsibility Plan.